{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:06Z","timestamp":1790957886749,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.mayocp.2015.08.010","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T10:01:15Z","timestamp":1444039275000},"page":"1440-1454","source":"Crossref","is-referenced-by-count":99,"title":["Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015"],"prefix":"10.1016","volume":"90","author":[{"given":"Philip A.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2015.08.010_bib1","doi-asserted-by":"crossref","unstructured":"Melo JV, Hughes TP, Apperley JF. Chronic Myeloid Leukemia. In: ASH Education Program Book 2003:132\u2013152.","DOI":"10.1182\/asheducation-2003.1.132"},{"issue":"6020","key":"10.1016\/j.mayocp.2015.08.010_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"issue":"4946","key":"10.1016\/j.mayocp.2015.08.010_bib3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"issue":"4944","key":"10.1016\/j.mayocp.2015.08.010_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.mayocp.2015.08.010_bib5","series-title":"World Health Organization Classification of Tumors of Haematopoietics and Lymphoid Tissues","year":"2008"},{"issue":"3","key":"10.1016\/j.mayocp.2015.08.010_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2015.08.010_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period","volume":"96","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.08.010_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(90)90119-X","article-title":"Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia","volume":"88","author":"Kantarjian","year":"1990","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2015.08.010_bib9","first-page":"208","article-title":"P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?","volume":"8","author":"Melo","year":"1994","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mayocp.2015.08.010_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.2830270202","article-title":"Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome","volume":"27","author":"Stoll","year":"1988","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2015.08.010_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.08.010_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.mayocp.2015.08.010_bib13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.08.010_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"issue":"19","key":"10.1016\/j.mayocp.2015.08.010_bib15","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","article-title":"EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience","volume":"119","author":"Jabbour","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2015.08.010_bib16","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.08.010_bib17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1\u2013mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in\u00a0vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2015.08.010_bib18","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2015.08.010_bib19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2015.08.010_bib20","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2015.08.010_bib21","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2015.08.010_bib22","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.08.010_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2015.08.010_bib24","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.11729","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"98","author":"Medina","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.mayocp.2015.08.010_bib25","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2015.08.010_bib26","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","article-title":"Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"108","author":"Kovitz","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.08.010_bib27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocp.2015.08.010_bib28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocp.2015.08.010_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJM198601233140403","article-title":"Bone marrow transplantation for patients with chronic myeloid leukemia","volume":"314","author":"Goldman","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2015.08.010_bib30","first-page":"509","article-title":"Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone marrow transplantation for chronic myeloid leukemia: long-term results","volume":"12","author":"Gratwohl","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.mayocp.2015.08.010_bib31","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1182\/blood.V84.5.1672.1672","article-title":"Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase","volume":"84","author":"Snyder","year":"1994","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.08.010_bib32","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V80.5.1352.1352","article-title":"Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2015.08.010_bib33","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1200\/JCO.1987.5.7.1033","article-title":"Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation","volume":"5","author":"McGlave","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.08.010_bib34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","article-title":"Identical-twin bone marrow transplants for leukemia","volume":"120","author":"Gale","year":"1994","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2015.08.010_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","article-title":"Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha","volume":"102","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2015.08.010_bib36","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2015.08.010_bib37","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2015.08.010_bib38","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2015.08.010_bib39","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.mayocp.2015.08.010_bib40","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2015.08.010_bib41","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2015.08.010_bib42","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cncr.25438","volume":"117","author":"Cortes","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2015.08.010_bib43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.08.010_bib44","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2015.08.010_bib45","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.mayocp.2015.08.010_bib46","first-page":"5s","article-title":"ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM)","volume":"32","author":"Larson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2015.08.010_bib47","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.mayocp.2015.08.010_bib48","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.mayocp.2015.08.010_bib49","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2015.08.010_bib50","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3026(15)00021-6","article-title":"Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.mayocp.2015.08.010_bib51","article-title":"Epic: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML)","volume":"124","author":"Lipton","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2015.08.010_bib52","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2015.08.010_bib53","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2353\/jmoldx.2007.060134","article-title":"Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations","volume":"9","author":"Zhang","year":"2007","journal-title":"J\u00a0Mol Diagn"},{"issue":"19","key":"10.1016\/j.mayocp.2015.08.010_bib54","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.mayocp.2015.08.010_bib55","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2015.08.010_bib56","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.mayocp.2015.08.010_bib57","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","article-title":"Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?","volume":"29","author":"Jabbour","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.mayocp.2015.08.010_bib58","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2015.08.010_bib59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.08.010_bib60","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","article-title":"Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months","volume":"98","author":"Nazha","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.mayocp.2015.08.010_bib61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.08.010_bib62","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.mayocp.2015.08.010_bib63","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2011-11-393041","article-title":"BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management","volume":"119","author":"Branford","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.mayocp.2015.08.010_bib64","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2015.08.010_bib65","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2015.08.010_bib66","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2015.08.010_bib67","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2015.08.010_bib68","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","article-title":"Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.mayocp.2015.08.010_bib69","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.08.010_bib70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.mayocp.2015.08.010_bib71","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","article-title":"Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.08.010_bib72","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.mayocp.2015.08.010_bib73","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.08.010_bib74","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2015.08.010_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4559.4559","article-title":"Bosutinib as third-line therapy in patients (Pts) with chronic phase chronic myeloid leukemia (CP CML) following failure with imatinib plus dasatinib and\/or nilotinib: 48-month update of a phase 1\/2 study","volume":"124","author":"Gambacorti-Passerini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.08.010_bib76","doi-asserted-by":"crossref","unstructured":"Mauro MJ, Cortes JE, Hochhaus A, et\u00a0al. Ponatinib efficacy and safety in patients with the t315i mutation: long-term follow-up of phase 1 and phase 2 (PACE) trials. 2014;124(21):4552-4552.","DOI":"10.1182\/blood.V124.21.4552.4552"},{"key":"10.1016\/j.mayocp.2015.08.010_bib77","unstructured":"US Food and Drug Administration. 2013 [cited 2015 8 Aug]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203469s007s008lbl.pdf."},{"key":"10.1016\/j.mayocp.2015.08.010_bib78","unstructured":"US Food and Drug Administration. Full Prescribing Information for Omacetaxine 2014 [cited 2015 8 Aug]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/203585s003lbl.pdf."},{"issue":"5","key":"10.1016\/j.mayocp.2015.08.010_bib79","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ajh.23408","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes","year":"2013","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.mayocp.2015.08.010_bib80","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2015.08.010_bib81","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.08.010_bib82","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2015.08.010_bib83","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2015.08.010_bib84","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3109\/10428194.2013.831092","article-title":"Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience","volume":"55","author":"Benjamini","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.mayocp.2015.08.010_bib85","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V122.21.4020.4020","article-title":"Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib","volume":"122","author":"Nicolini","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2015.08.010_bib86","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.V124.21.812.812","article-title":"Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK-cells","volume":"124","author":"Ilander","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.08.010_bib87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","volume":"14","author":"Ohanian","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.mayocp.2015.08.010_bib88","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","article-title":"First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia","volume":"26","author":"Rea","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.mayocp.2015.08.010_bib89","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML","volume":"100","author":"O'Dwyer","year":"2002","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2015.08.010_bib90","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2015.08.010_bib91","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2015.08.010_bib92","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood.V84.12.4368.bloodjournal84124368","article-title":"Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"issue":"9134","key":"10.1016\/j.mayocp.2015.08.010_bib93","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mayocp.2015.08.010_bib94","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2015.08.010_bib95","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.28433","article-title":"HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia","volume":"120","author":"Strati","year":"2014","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.mayocp.2015.08.010_bib96","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.mayocp.2015.08.010_bib97","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","article-title":"Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients","volume":"86","author":"Sacchi","year":"1999","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.mayocp.2015.08.010_bib98","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2015.08.010_bib99","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2015.08.010_bib100","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","article-title":"Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis","volume":"109","author":"Fruehauf","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2015.08.010_bib101","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","article-title":"A\u00a0pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase","volume":"48","author":"Quintas-Cardama","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.mayocp.2015.08.010_bib102","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood-2002-05-1366","article-title":"High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML","volume":"101","author":"Lange","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2015.08.010_bib103","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2002-10-3059","article-title":"The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia","volume":"101","author":"Wolff","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2015.08.010_bib104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.mayocp.2015.08.010_bib105","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.mayocp.2015.08.010_bib106","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24034","article-title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors","volume":"90","author":"Gambacorti-Passerini","year":"2015","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.mayocp.2015.08.010_bib107","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615006710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615006710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T09:25:36Z","timestamp":1583918736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619615006710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":107,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0025619615006710"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.08.010","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}